IGC Pharma, Inc. (NASDAQ:IGC) | WebDisclosure

Basculer en Français

8296	Companies
114899	Keywords
55318	Articles
62453	Press releases

Home
Companies
IGC Pharma, Inc.

BRIEF

published on 11/14/2024 at 14:35, 6 days 22 hours ago

IGC Pharma Reports Financial and Strategic Milestones for Q2 FY2025

Financial Results Revenue Growth IGC Pharma Alzheimer's Treatments R&D Advancements
BRIEF

published on 11/14/2024 at 14:35, 6 days 22 hours ago

IGC Pharma annonce les étapes financières et stratégiques du deuxième trimestre de l'exercice 2025

Résultats Financiers Croissance Des Revenus IGC Pharma Traitements De La Maladie D'Alzheimer Progrès En R&D
PRESS RELEASE

published on 11/14/2024 at 14:30, 6 days 22 hours ago

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
IGC Pharma, Inc. announces Q2 FY2025 financial results and strategic advancements including breakthroughs in Alzheimer's treatment pipeline. Revenue grows 42% to $412k. R&D expenses decrease 28%

Financial Results R&D Expenses Q2 FY2025 IGC Pharma Alzheimer's Treatment
BRIEF

published on 11/06/2024 at 14:35, 14 days 22 hours ago

IGC Pharma Highlights Strategic Advances in Alzheimer's and Weight Loss Therapies

Weight Loss Artificial Intelligence GLP-1 Agonists IGC Pharma Alzheimer's Treatment
BRIEF

published on 11/06/2024 at 14:35, 14 days 22 hours ago

IGC Pharma met en avant des avancées stratégiques dans les thérapies contre la maladie d'Alzheimer et la perte de poids

Intelligence Artificielle Perte De Poids Agonistes Du GLP-1 IGC Pharma Traitement De La Maladie D'Alzheimer
PRESS RELEASE

published on 11/06/2024 at 14:30, 14 days 22 hours ago

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
IGC Pharma, Inc. (NYSE American: IGC) announces a new interview with CEO Ram Mukunda discussing strategic expansion into metabolic and neurological markets, focusing on Alzheimer's and weight loss therapies, leveraging AI for diverse pipeline

Interview Neurodegenerative Disorders Metabolic Disorders IGC Pharma Ram Mukunda
BRIEF

published on 10/17/2024 at 14:35, 1 month 3 days ago

IGC Pharma Expands Alzheimer's Trial to Canada with Baycrest Partnership

IGC Pharma Alzheimer's Trial IGC-AD1 Baycrest Partnership Phase 2 Clinical
BRIEF

published on 10/17/2024 at 14:35, 1 month 3 days ago

IGC Pharma étend son essai sur la maladie d'Alzheimer au Canada grâce à un partenariat avec Baycrest

IGC Pharma IGC-AD1 Essai Sur La Maladie D'Alzheimer Partenariat Baycrest Phase 2 Clinique
PRESS RELEASE

published on 10/17/2024 at 14:30, 1 month 3 days ago

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
IGC Pharma expands Phase 2 trial to Canada at Baycrest Academy for Research and Education in Toronto, Ontario, to investigate IGC-AD1 for treating agitation in Alzheimer's dementia

Phase 2 Trial Alzheimer's IGC Pharma Agitation Treatment Baycrest Academy
BRIEF

published on 10/03/2024 at 15:05, 1 month 17 days ago

IGC Pharma Secures Two Awards in NIH's AI PREPARE Challenge

AI Technology Healthcare Innovation IGC Pharma Alzheimer's Prediction NIH Challenge

Accesswire

Published on 11/21/2024 at 13:00, 18 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 18 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 18 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 18 minutes ago

Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 18 minutes ago

Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 12:35, 43 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 3 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 11 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 18 minutes ago

Holding(s) in Company
Published on 11/21/2024 at 11:30, 1 hour 48 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 20 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 20 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 20 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 17 hours 11 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 58 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE